Processa Pharmaceuticals shares are trading higher after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals shares are trading higher after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.
July 30, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Processa Pharmaceuticals shares are trading higher following FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.
The FDA clearance for a Phase 2 clinical trial is a significant milestone for Processa Pharmaceuticals, indicating potential progress in their breast cancer treatment development. This positive regulatory news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100